Fri, Sep 19, 2014, 9:32 AM EDT - U.S. Markets close in 6 hrs 28 mins

Recent

% | $
Quotes you view appear here for quick access.

Northwest Biotherapeutics, Inc. Message Board

steven511825 27 posts  |  Last Activity: 18 hours ago Member since: Mar 12, 2014
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Puma Biotec (now at 49 employees) PBYI
    Sep 13 $60
    Oct 13 $33
    Nov 13 $70
    Jan 14 $143
    Jun 14 $ 56 !!!!! ouchhhhh ......
    Now $ 273 with an $8bn market cap .

  • steven511825 by steven511825 Sep 11, 2014 4:29 AM Flag

    I emailed Les Goldman , asking him for a better understanding of the process of German reimbursement negotiations , as yet no response .
    Hopefully he is busy petitioning Dr Seigel, Fox News , The BBC , the German TV stations and newspapers & The Daily Mail in the UK which has the worlds most popular newspaper website, the list really is endless... anyway he has a great story to tell but for my part I don't see any traction whatsoever.
    Even looking at the initiative Highwayman is taking (well done btw) really should be NW`s PR department.
    Les doesn't have to be the guy to make the calls he simply needs to retain a major PR company for 3 months ,the results would be seen immediately.
    I think I certainly got worried over `the imminent 88th event` affair and when the full story of the 55 was told there was good reason for the radio silence , I want to believe that the lack of commercial PR has a reason , maybe there`s an NDA ... that would explain why NW PR is only on the most basic level.

    Sentiment: Strong Buy

  • If I were an institutional investor , the deflated share price and huge number of shorts would scream that `they` know something I don't , and the old adage` if it looks too good to be true it probably aint `wouldn't be far behind . We are long and have seen how this stock has been battered by HF`s , and Option market maker manipulation , which gives me `some` comfort but no one is buying till German negotiations are disclosed . LP saying `News this Autumn` is positive , but the urgency of a definitive reimbursement number is exacerbated by the fact large Pharma no doubt want us to crash and burn . My message to LP would be don't sacrifice the dollars for the sake of the cents , get a deal done now , get the number out to the street , even the ball park number would work for an immediate fix ,analyst would start coverage of NWBO, the veiled threat of Large Pharma / HF and alike would disappear immediately , shares would pop , shorts would get stopped and the price would pop again , the market cap would be in the billions and her product , the game changing word beating life saving technology would be available to huge numbers of people much much sooner .... if its really about the patients , get a deal done , as a share holder I would not critisize a discounted deal for Germany. Thks

  • steven511825 steven511825 Sep 8, 2014 11:48 AM Flag

    And the update is tomorrow anyway ...

  • steven511825 steven511825 Sep 8, 2014 8:51 AM Flag

    BETHESDA, Md., Sept. 8, 2014 /PRNewswire/ -- Northwest Biotherapeutics (NASDAQ: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today that Linda F. Powers, CEO, will present at 2:05 pm on TUESDAY, September 9, 2014

  • steven511825 steven511825 Sep 8, 2014 8:38 AM Flag

    Sure, anhe_58 , if we get German pricing tomorrow we really will be home and dry ,so hoping for the best but kind of expect that if she has that information she would be bound ( morally at least ) to release it immediately and not wait for a presentation at a commercial event .

  • NW BIO TO PRESENT UPDATES AT RODMAN RENSHAW 16TH ANNUAL GLOBAL INVESTMENT CONFERENCE
    PR Newswire

    BETHESDA, Md., Sept. 8, 2014

    BETHESDA, Md., Sept. 8, 2014 /PRNewswire/ -- Northwest Biotherapeutics (NASDAQ: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today that Linda F. Powers, CEO, will present at 2:05 pm on Tuesday, September 9, 2014, in the Holmes I Salon at the Palace Hotel in New York as part of the Rodman & Renshaw 16th Annual Global Investment Conference.

  • steven511825 steven511825 Sep 5, 2014 8:38 AM Flag

    Wow , what a superb story/ clip for everyone involved ..

    Sentiment: Strong Buy

  • Reply to

    Hi Ctixer & Kruk

    by steven511825 Sep 1, 2014 2:07 PM
    steven511825 steven511825 Sep 2, 2014 10:03 AM Flag

    Highwayman - Sorry I missed your response on Ihub . Certainly wasn't intentional .

    You chaps can get on with your 'Yea ! Go NWBO !!` posts till your heart`s content , they will be unchallenged by me at least .

    And for the last time :
    `Fanaticism is over compensation for doubt ` Napoleon . ( Basher / Paid short no doubt .. )

  • Reply to

    Hi Ctixer & Kruk

    by steven511825 Sep 1, 2014 2:07 PM
    steven511825 steven511825 Sep 1, 2014 5:26 PM Flag

    No thats fair enough ,out of context it could be bashing but check out all my posts and its easy to see the truth .

    Also when I told Xena where he / she was going wrong with the charts that he / she is trying to convince us are still in an up trend when they no longer are ...Now thats more disturbing than me suggesting a downside of $4 in the event of no news .

    So I have a question.. rhetorical or not your choice ....
    Would you rather I posted "Yea Go NWBO !! " as others do , or " This is an opportunity to buy more " As we drop 10 cents a day ...? .

    Anyway you never know we might open at $125 tomorrow , if we do I promise to spend $1m suing AF if it does :)

  • steven511825 by steven511825 Sep 1, 2014 2:07 PM Flag

    Yep Im Baby Basin Crying Whining Baby Blues whatever other insulting term or unfunny alliteration you'd care to bolt on ...

    Ctixers, agreed, awareness is great but we've all referred to ICPT as being the dream scenario , 70 - 250 - 500 in two days , that happend because there was an institutional holding above 80% that didn't sell at 250 and therefore gave retail , ( you and I ) a second dream day to sell easily in the high 400's , good luck to the cancer special TV show but other than give us some comfort to hear our companies name dont expect too much or youll be disappointed .

    Kruk , Yep im long , not at 6.50 at 6.86 , and believe me I would not be long if i didnt believe the story .
    The darling of the boards Pyrr suggested I was confused when I posted I was 200k long , I asked him to drop me a private post and I would tell him who I am and what I hold ,,, he didn't .

    You'll all remember when AF ran out of bulls*** to sling at us , he started attacking the journalists ( Larry Smith )
    that precisely whats happened to me - I told Ihub , I love the posts but frankly dont take a blind bit of notice of their incessant pseudo progression modelling etc etc , BECAUSE WHATEVER THEY COME UP WITH , ITS WITH LESS KNOWLEDGE THAN THE STATISTICIANS THAT WORK FOR THE LARGE PHARMA'S AND THAT EVALUATE PHARMA, SHOWIN US AS 7TH WITH NO ALIGNMENT OF LARGE PHARMA SUITOR , I READ AS BAD NEWS . then Pyrr and Flipper freaked... and made personal posts against me...our academic demi god Pyrr even telling me how unhappy I must be ... hysterical .

    Please check my posts, its easy enough , I post good news quicker than anyone because im in front of a terminal , but I simply got tired of the big posters on Ihub jerking each other off .. ( sorry had to wrote that as it made me laugh ) suggesting theyve made significant fidnings that by definition Large Pharma had not otherise wed already be at $12 ++

    " Fanaticism is over compensation for doubt " Napoleon .

    All the best .

  • NWBO is making multiple progresses in its ongoing Phase III clinical trial of
    DCVax-L for brain cancer and Phase I/II trial of DCVax-Direct for solid
    tumors. Phase III of DCVax-L has been enrolling patient in the US, UK, and
    Germany. Hospital Exemption in Germany further validates its immunotherapy
    platform. Positive data from Phase I/II study of DCVax-Direct reported.

    Current valuation is attractive.
    We maintain our Outperform rating.

    Provider ID: NWBO_SCIR_20140827_ZXCVBNMLKJHGF

  • August 24, 2014 5:05 pm

    By Andrew Ward and Arash Massoudi in London

    Roche has agreed to buy InterMune, the US biotech company, for $8.3bn in the latest example of the feverish deal activity sweeping the pharmaceuticals sector.
    The all-cash transaction – Roche’s biggest acquisition for five years – will give the Swiss group access to InterMune’s new medicine for a previously untreatable lung disease, highlighting the push by big pharma into so-called orphan drugs for rare or incurable conditions.

  • steven511825 by steven511825 Aug 14, 2014 7:32 AM Flag

    you may be the only source of information from yesterdays conference ...

  • steven511825 steven511825 Aug 12, 2014 11:42 AM Flag

    Shocking behviour , SEC are spineless.

  • Reply to

    How can anyone see this as negative

    by cumberlandcoach Aug 11, 2014 9:34 AM
    steven511825 steven511825 Aug 11, 2014 9:46 AM Flag

    Im long , very long and am pleased with the PR , but if its that good in a random group of 55 that were outside of the trial , therefore they are effectively a free `look ` for us , why on earth hasnt the trial been stopped for efficacy and ethical grounds .... it doesnt add up .. I`d appreciate any ideas why this has not been stopped , approved and rushed to patients everywhere ?

  • steven511825 by steven511825 Aug 11, 2014 8:23 AM Flag

    NW BIO OBTAINS APPROVALS FOR ENHANCEMENTS OF PHASE III TRIAL OF DCVAX®-L FOR GBM BRAIN CANCER
    Important New Variable Covered. Threshold for Meeting Primary Endpoint Lowered.
    Company Remains Blinded, With No Access to Trial Data At Any Time
    PR Newswire
    BETHESDA, Md., Aug. 11, 2014
    BETHESDA, Md., Aug. 11, 2014 /PRNewswire/ -- Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today that, following a 9-month process of regulatory submissions and reviews by regulators in the US, UK and Germany, it has obtained regulatory approvals to make certain enhancements to its ongoing Phase III clinical trial of DCVax-L Glioblastoma multiforme (GBM) brain cancer. The enhancements will allow the statistical analysis of trial results to take account of a major new variable which has been identified in GBM research since the Company's Phase III trial began, and will lower the threshold for satisfying the primary endpoint of the trial.
    The Company has been blinded at all times, with no access to any data in the Phase III trial, and will remain fully blinded until the trial is completed. The changes relate to the statistical analyses that will be done at the end of the trial, and do not affect the treatment protocol, dosing, randomization of patients or other such aspects. The changes were driven solely by external factors -- particularly research reports about a newly discovered variable which has been found to significantly affect GBM patients' survival times, and which the Company recognized could significantly skew the clinical trial results if the trial's statistical analyses did not control for it. The Company's Phase III trial design and statistical analyses already controlled for key variables known at the time when the trial was designed, such as a particular genetic factor (referred to as MGMT methylation), the extent of tumor removal, and others.
    The new variable i

  • Short interest as reported by Nasdaq and Bloomberg for 30/6 is 6.995m....
    Why you posted 13m is beyond me as these are public domain numbers , I can only suppose your`e a basher , but one thats too stupid to realise if it got to those levels of shorts , IT DRIFTS UP .... loser ..

  • So ...our extrapolated dates for the 88th event were incorrect, that means that the trial has not got to the required number of deaths or tumor recurrences that would allow the announcement. This in turn means that the projected dates that were based on good results from earlier releases would have already been favorable if and when they were reached. The fact they haven’t reached this milestone yet means that the vaccine is working above and beyond what were already levels far beyond the results achieved in current SOC ... Therefore when the 88th event occurs and the data is then released that data will blow us all away with its new standards .
    The share price will increase dramatically, for two reasons , firstly of course L has its own life and value but more importantly it will mean smart money will accept D has a significantly greater chance of at the very least matching the current SOC PFS BUT WITH ZERO SIDE EFFECTS , therefore huge swaths of sufferers will commute on their own insistence to DCVac , this in its own right will mean a huge potential for the stock price , however if D produces the stellar results we all expect , the world has change , and for many of you with even a modest long position the boss can ` Poke it where the sun don’t shine ! .`
    So shorts are probably short at an average of $6.00 if they were lucky, with a potential profit of $3 should everything go wrong and NWBO are just left with German revenue
    Short term trading view :
    Short POTENTIAL = + $3 ( $6 to $3 )
    Long POTENTIAL = + $119 ( $6 to $125)
    Medium Term trading view
    Short POTENTIAL = + $3 ( $6 to $3 )
    Long POTENTIAL = + $244 ( $6 to $250)
    Long Term trading view
    Short POTENTIAL = + $3 ( $6 to $3 )
    Long POTENTIAL = + $494 ( $6 to $500)

  • steven511825 by steven511825 Jul 9, 2014 3:22 AM Flag

    “There is a principle which is a bar against all information, which is proof against all arguments, and which cannot fail to keep a man in everlasting ignorance—that principle is contempt prior to investigation.”
    William Paley . 1743 - 1805

    Sentiment: Strong Buy

NWBO
5.64-0.03(-0.53%)9:30 AMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.